Madrigal Q2 Revenue Jumps 71% to $364M as Rezdiffra Patients Exceed 49,000
MDGL sits 86% above its 52-week low of $286.44.
Summary
Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3 million, up 71% year-over-year, with over 49,000 patients on therapy. The company initiated a Phase 1 trial for oral GLP-1 candidate MGL-2086 and secured three new patents, extending IP protection into the 2040s.
Updates
· Reuters — Q2 revenue rose 71% year-over-year to $364.25 million, with net loss widening to $57.94 million and operating expenses of $420.56 million.
Key Events · Earnings and Guidance · MDGL
-
Rezdiffra Sales Surge 71%
Q2 2026 net revenues reached $364.3 million, up from $212.8 million in Q2 2025, driven by strong demand and over 49,000 patients on therapy as of June 30, 2026.
-
Pipeline Advancement with MGL-2086
Dosing initiated in a Phase 1 single ascending dose trial for oral GLP-1 candidate MGL-2086, supporting a combination strategy with Rezdiffra for MASH.
-
IP Portfolio Strengthened
Three new U.S. patents issued for resmetirom, including protection for F4c cirrhosis use and drug-drug interaction management, extending exclusivity into 2042-2045.
-
Financial Position Remains Strong
Cash, cash equivalents, restricted cash, and marketable securities totaled $838.9 million as of June 30, 2026, down from $988.6 million at year-end 2025, reflecting continued investment in commercialization and pipeline.
Analysis · MDGL · Life Sciences
Another strong quarter for Madrigal saw Rezdiffra net sales climb 71% year-over-year to $364.3 million, fueled by rapid patient adoption—more than 49,000 patients are now on therapy, more than double the prior year. The pipeline also advanced, with the first patients dosed in a Phase 1 trial for oral GLP-1 candidate MGL-2086, while three new patents extended IP protection into the 2040s. Despite a net loss of $57.9 million, the $838.9 million cash position provides ample runway. These results reinforce Madrigal's leadership in the expanding MASH market and its strategy to build a next-generation combination therapy franchise.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDGL was trading at $533.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $286.44 to $615.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.